Devyn Smith

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of advanced therapies and modernize healthcare systems so that patients benefit from durable, potentially curative treatments. As the global voice of the sector, we represent more than 475 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of advanced therapies and modernize healthcare systems so that patients benefit from durable, potentially curative treatments. As the global voice of the sector, we represent more than 475 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Frankel Group is a leading strategy consulting firm with offices in New York City, Cambridge, Massachusetts, and Tel Aviv, Israel that has served the life science industry and related segments since 1993. The firm serves a diverse client base including global, specialty and multi-source pharmaceutical, emerging bio/pharmaceutical, device/diagnostic and life science IT firms, as well as investment groups serving the life sciences industry. Frankel Group’s strategic solutions include Corporate Strategy, R&D Optimization, LM&A Advisory, and Commercialization Strategy. The strength of our organization is built upon the quality of our staff, which holds a multitude of advanced degrees in both science and business pursuits. Our people come from backgrounds in industry, banking, payor organizations, professional services, and other stakeholder positions prior to joining FG, which results in deep expertise across the life sciences value chain. Clients come to, and stay with FG due to our proven track record of quality and service. We specialize in the business of life sciences and provide focused, experienced teams that deliver consistent high quality solutions.